Bevacizumab improves the delivery and efficacy of paclitaxelYanagisawa, Miekoa; Yorozu, Keigoa; Kurasawa, Mitsuea; Nakano, Kohnosukeb; Furugaki, Koha; Yamashita, Yorikoa; Mori, Kazushigea; Fujimoto-Ouchi, KaoriaAnti-Cancer Drugs: August 2010 - Volume 21 - Issue 7 - p 687-694 doi: 10.1097/CAD.0b013e32833b7598 Preclinical Reports Abstract Author Information It has been reported that bevacizumab in combination with paclitaxel significantly prolongs progression-free survival compared with paclitaxel alone in the initial treatment for metastatic breast cancer. To understand how bevacizumab enhances the efficacy of paclitaxel, we investigated the mechanism in a MX-1 human breast cancer xenograft model. The antitumor activity of bevacizumab at 5 mg/kg in combination with paclitaxel at 20 or 30 mg/kg was significantly higher than that of either agent alone. First, we measured the paclitaxel concentration in tumor to see whether bevacizumab enhances the activity by increasing the tumor concentration of paclitaxel. When given in combination with bevacizumab, the levels of paclitaxel in the tumor increased. Paclitaxel at 30 mg/kg with bevacizumab showed a similar tumor concentration as paclitaxel alone at either 60 or 100 mg/kg, with a similar degree of tumor growth inhibition. In contrast, no remarkable differences in paclitaxel concentration in the plasma or liver were observed between the paclitaxel monotherapy group and the paclitaxel plus bevacizumab group. An increase in paclitaxel concentration by bevacizumab was also found in another model, A549. In the same MX-1 model, vascular permeability in the tumor was significantly decreased by treatment with bevacizumab. There was no difference in microvessel density between the bevacizumab alone group and the combination group. Results suggest that the synergistic antitumor activity of paclitaxel and bevacizumab in combination may be a result of the increase in paclitaxel concentration in tumor resulting from the downregulation of vascular permeability when co-administered with bevacizumab. Departments of aProduct Research bPre-clinical Research, Chugai Pharmaceutical Co., Ltd., Kajiwara, Kamakura, Japan Correspondence to Kaori Fujimoto-Ouchi, PhD, Department of Product Research, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura 247-8530 Japan Tel: +81 467 45 7692; fax: +81 467 45 7643; e-mail: firstname.lastname@example.org Received 19 January 2010 Revised form accepted 28 April 2010 © 2010 Lippincott Williams & Wilkins, Inc.